Skip to main content
Premium Trial:

Request an Annual Quote

Company That Brought Genomics the 384 Wellplate Plans IPO

NEW YORK, Oct 11 - What’s six inches by four inches, has more than three hundred holes, and is about to make one company very rich?

If you guessed the 384 Wellplate, you’re right on the money.

Genetix, the company that brought genomics the 384 Wellplate is planning to float shares in an initial public offering next month on the London Stock Exchange, the British Ananova website reported Wednesday.

According to Ananova, Genetix of New Forest, UK, hopes to raise 27 million pounds ($39.5 million) via the offering.

The company generates annual profits of 3.2 million pounds through sales of a range of machinery including the 384 Wellplate to such cutomers as Glaxo Wellcome, AstraZeneca, and Millennium Pharmaceuticals. The company recently began selling in China and has plans to enter the Brazilian market later this month.

The company is expected to issue a shareholder prospectus Thursday.

A float price will be disclosed on October 31, and the company hopes to start trading on November 7.

Genetix has 60 employees.

The Scan

Myotonic Dystrophy Repeat Detected in Family Genome Sequencing Analysis

While sequencing individuals from a multi-generation family, researchers identified a myotonic dystrophy type 2-related short tandem repeat in the European Journal of Human Genetics.

TB Resistance Insights Gleaned From Genome Sequence, Antimicrobial Response Assays

Researchers in PLOS Biology explore M. tuberculosis resistance with a combination of sequencing and assays looking at the minimum inhibitory concentrations of 13 drugs.

Mendelian Disease Genes Prioritized Using Tissue-Specific Expression Clues

Mendelian gene candidates could be flagged for further functional analyses based on tissue-specific transcriptome and proteome profiles, a new Journal of Human Genetics paper says.

Single-Cell Sequencing Points to Embryo Mosaicism

Mosaicism may affect preimplantation genetic tests for aneuploidy, a single-cell sequencing-based analysis of almost three dozen embryos in PLOS Genetics finds.